Assessment of Patient –Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study
ConclusionsIn this study, few patients with PsA were at risk of suboptimal communication with their physician. This phenomenon appeared to be primarily related to higher disease activity and burden. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 6, 2024 Category: Rheumatology Source Type: research
Rehabilitation of patients with inflammatory rheumatic diseases and comorbidities: unmet needs
AbstractComorbidities may contribute to inadequate response to therapy and accelerate disability in various rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and psoriatic arthritis (PsA). Cardiovascular, oncological, and infectious comorbidities are common in rheumatic patients. The rehabilitation of patients with inflammatory rheumatic diseases (IRDs) with comorbidities requires a multidisciplinary approach to improving patients ’ functional mobility, slowing down the disease progression and minimizing the risks of complications. The evidence suggests that cardiac rehabilitation ...
Source: Rheumatology International - March 5, 2024 Category: Rheumatology Source Type: research
Exploring 5-year changes in general and skin health-related quality of life in psoriatic arthritis patients
AbstractPsoriatic arthritis (PsA) carries a severe disease burden, often leading to deterioration of health-related quality of life (HRQoL). Different comorbidities that are relatively prevalent in PsA are also responsible for compromised HRQoL. To assess real-world data of a 5-year follow-up cohort of PsA patients, focusing on changes in general HRQoL, skin HRQoL, and comorbidities. In this prospective observational study, 114 outpatients diagnosed with PsA were examined at baseline and after 5 years. Data collection included demographics, clinical disease activity measures, and patient-reported outcome measures (PROMs)...
Source: Rheumatology International - March 5, 2024 Category: Rheumatology Source Type: research
Satisfaction with the Injection Experience of a New, Citrate-Free Formulation of Ixekizumab
ConclusionThe citrate-free ixekizumab formulation was preferred and well accepted by most patients who switched from the original ixekizumab formulation. Similar findings were seen for those newly initiating citrate-free ixekizumab. (Source: Advances in Therapy)
Source: Advances in Therapy - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis
CONCLUSION: This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.PMID:38435412 | PMC:PMC10907062 | DOI:10.1093/rap/rkae018 (Source: Adv Data)
Source: Adv Data - March 4, 2024 Category: Epidemiology Authors: Jake Weddell Naw Ra Aung Din Stephanie R Harrison Xabier Michelena Dennis McGonagle Andrew Barr Claire Vandevelde Jane Freeston Helena Marzo-Ortega Source Type: research
Real ‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study
(Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - March 4, 2024 Category: Rheumatology Authors: Salvatore D'Angelo,
Enrico Tirri,
Angela Maria Giardino,
Tiziana De Rosa,
Marco Matucci‐Cerinic,
Lorenzo Dagna,
Leonardo Santo,
Francesco Ciccia,
Bruno Frediani,
Marcello Govoni,
Francesca Bobbio Pallavicini,
Rosa Daniela Grembiale,
Andrea Tags: LETTER TO THE EDITOR Source Type: research
Modulation of Interleukin ‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
ConclusionGuselkumab modulates IL-23 signaling and provides consistent pharmacodynamic effects in both biologic-naive and TNFi-IR PsA patients. Significantly elevated baseline IL-22, TNF α, and BD-2 levels and associations between baseline IL-22, IL-17A, and BD-2 levels and skin responses to guselkumab suggest greater dysregulation of IL-23/Th17 signaling in patients with TNFi-IR. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - March 4, 2024 Category: Rheumatology Authors: Stefan Siebert,
Laura C. Coates,
Georg Schett,
Siba P. Raychaudhuri,
Warner Chen,
Sheng Gao,
Loqmane Seridi,
Soumya D. Chakravarty,
May Shawi,
Frederic Lavie,
Mohamed Sharaf,
Miriam Zimmermann,
Alexa P. Kollmeier,
Xie L. Xu,
Proton Rahman,
Tags: Full Length Source Type: research
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study
ConclusionThe “real-life” 6-month effectiveness of guselkumab was shown in patients with PsA, mainly characterised by active long-standing disease, previously treated with bDMARDs, and with comorbidities. Furthermore, a good DRR of guselkumab was estimated in the cumulative 18 months of follow-up and appeare d to be not influenced by long disease duration, comorbidities, obesity, and previous bDMARDs. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 4, 2024 Category: Rheumatology Source Type: research
Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases
ConclusionsAcross three rheumatologic diseases, about half of patients persisted on ABP 501 at the end of 12 months after treatment initiation in both Germany and France. Patients experienced with ADA were more likely to switch back to ADA RP, regardless of indication and country, suggesting a possible nocebo effect. Future studies are warranted to understand reasons of discontinuation and switching. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 4, 2024 Category: Rheumatology Source Type: research
Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis
J Rheumatol. 2024 Mar 1;51(3):318-320. doi: 10.3899/jrheum.2023-0909.NO ABSTRACTPMID:38428986 | DOI:10.3899/jrheum.2023-0909 (Source: J Rheumatol)
Source: J Rheumatol - March 1, 2024 Category: Rheumatology Authors: Rebecca H Haberman Ying Yin Zhou Sydney Catron Adamary Felipe Kathryn Jano Soumya M Reddy Jose U Scher Source Type: research
Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis
J Rheumatol. 2024 Mar 1;51(3):318-320. doi: 10.3899/jrheum.2023-0909.NO ABSTRACTPMID:38428986 | DOI:10.3899/jrheum.2023-0909 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - March 1, 2024 Category: Rheumatology Authors: Rebecca H Haberman Ying Yin Zhou Sydney Catron Adamary Felipe Kathryn Jano Soumya M Reddy Jose U Scher Source Type: research
Autoimmune diseases and female-specific cancer risk: A systematic review and meta-analysis
CONCLUSIONS: RA seems to reduce the risk of breast and uterine cancers, while PsO appears to increase breast cancer risk. Further large studies are required to investigate potential therapy-effects and detailed biological mechanisms.PMID:38428110 | DOI:10.1016/j.jaut.2024.103187 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - March 1, 2024 Category: Allergy & Immunology Authors: Simone Fischer Christa Meisinger Dennis Freuer Source Type: research
Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis
J Rheumatol. 2024 Mar 1;51(3):318-320. doi: 10.3899/jrheum.2023-0909.NO ABSTRACTPMID:38428986 | DOI:10.3899/jrheum.2023-0909 (Source: J Rheumatol)
Source: J Rheumatol - March 1, 2024 Category: Rheumatology Authors: Rebecca H Haberman Ying Yin Zhou Sydney Catron Adamary Felipe Kathryn Jano Soumya M Reddy Jose U Scher Source Type: research
Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis
J Rheumatol. 2024 Mar 1;51(3):318-320. doi: 10.3899/jrheum.2023-0909.NO ABSTRACTPMID:38428986 | DOI:10.3899/jrheum.2023-0909 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - March 1, 2024 Category: Rheumatology Authors: Rebecca H Haberman Ying Yin Zhou Sydney Catron Adamary Felipe Kathryn Jano Soumya M Reddy Jose U Scher Source Type: research
